← Back to Screener
Viatris Inc. Common Stock (VTRS)
Price$15.88
Value ScoreB
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)40.62%
Price vs S&P 500 (4W)-7.50%
VGM Score65.18
Market Capitalization$18.12B
Indicated Dividend Yield (Annual)3.09%
All Metrics
P/CF (Annual)7.82x
Book Value / Share (Quarterly)$12.59
P/TBV (Annual)9.50x
Indicated Dividend (Annual)$0.48
Revenue Growth (3Y)-4.20%
Cash Flow / Share (Quarterly)$1.42
Payout Ratio (TTM)79.14%
Price vs S&P 500 (YTD)19.39%
Gross Margin (TTM)39.82%
Net Profit Margin (TTM)-2.04%
EPS (TTM)$-0.26
10-Day Avg Trading Volume9.59M
EPS Excl Extra (TTM)$-0.26
Revenue Growth (5Y)3.66%
EPS (Annual)$-3.00
Dividend / Share (Annual)$0.48
ROI (Annual)-12.07%
Gross Margin (Annual)39.55%
Net Profit Margin (5Y Avg)-4.57%
Cash / Share (Quarterly)$1.94
Revenue Growth QoQ (YoY)8.07%
ROA (Last FY)-9.45%
Revenue Growth TTM (YoY)1.62%
EBITD / Share (TTM)$2.45
ROE (5Y Avg)-4.67%
Operating Margin (TTM)0.34%
Cash Flow / Share (Annual)$1.61
P/B Ratio1.24x
P/B Ratio (Quarterly)1.07x
Net Income / Employee (Annual)$-117,200
EV / Revenue (TTM)2.11x
Net Interest Coverage (TTM)-6.78x
ROA (TTM)-0.79%
EV / EBITDA (TTM)10.72x
EPS Incl Extra (Annual)$-3.00
Current Ratio (Annual)1.38x
Quick Ratio (Quarterly)0.92x
3-Month Avg Trading Volume11.04M
52-Week Price Return87.71%
EV / Free Cash Flow (Annual)16.56x
Revenue / Employee (TTM)$485,400
Tangible BV / Share (Quarterly)$0.15
P/S Ratio (Annual)1.27x
Asset Turnover (Annual)0.38x
52-Week High$17.53
Operating Margin (5Y Avg)-1.79%
EPS Excl Extra (Annual)$-3.00
CapEx CAGR (5Y)-7.35%
Tangible BV CAGR (5Y)29.84%
26-Week Price Return48.55%
Quick Ratio (Annual)0.70x
13-Week Price Return9.29%
Total Debt / Equity (Annual)0.98x
Current Ratio (Quarterly)1.60x
Enterprise Value$30.66B
Revenue / Share Growth (5Y)-9.28%
Asset Turnover (TTM)0.39x
Book Value / Share Growth (5Y)-7.64%
Revenue / Employee (Annual)$476,700
Inventory Turnover (Annual)2.20x
Pretax Margin (Annual)-25.63%
Cash / Share (Annual)$1.24
3-Month Return Std Dev32.72%
Gross Margin (5Y Avg)40.95%
Net Income / Employee (TTM)$-9,900
EBITDA CAGR (5Y)-56.10%
EBITDA Interim CAGR (5Y)-12.71%
ROE (Last FY)-23.89%
Net Interest Coverage (Annual)-0.71x
EPS Basic Excl Extra (Annual)$-3.00
P/FCF (TTM)10.94x
Receivables Turnover (TTM)5.64x
EV / Free Cash Flow (TTM)18.52x
Total Debt / Equity (Quarterly)0.98x
EPS Incl Extra (TTM)$-0.26
Receivables Turnover (Annual)5.44x
ROI (TTM)-1.01%
P/S Ratio (TTM)1.24x
Pretax Margin (5Y Avg)-2.99%
Revenue / Share (Annual)$12.21
Tangible BV / Share (Annual)$1.31
Forward P/E6.66x
Free OCF CAGR (5Y)27.44%
Price vs S&P 500 (52W)63.34%
Year-to-Date Return27.55%
5-Day Price Return0.44%
EPS Normalized (Annual)$-3.00
ROA (5Y Avg)-1.80%
Net Profit Margin (Annual)-24.58%
Month-to-Date Return-2.34%
Cash Flow / Share (TTM)$3.97
EBITD / Share (Annual)$0.03
Operating Margin (Annual)-19.34%
LT Debt / Equity (Annual)0.85x
P/CF (TTM)8.36x
ROI (5Y Avg)-2.33%
LT Debt / Equity (Quarterly)0.85x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)89.69x
Payout Ratio (Annual)28.47%
P/B Ratio (Annual)0.97x
Dividend / Share (TTM)$0.47
Inventory Turnover (TTM)2.18x
Pretax Margin (TTM)-5.60%
Book Value / Share (Annual)$12.78
Price vs S&P 500 (13W)1.04%
Dividend Yield (TTM)3.08%
Beta0.91x
P/FCF (Annual)9.79x
Revenue / Share (TTM)$12.39
ROE (TTM)-1.97%
52-Week Low$8.44
vGradeB
gGradeC
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.59est. 0.51
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.72
3.83
3.83
3.83
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VTRSViatris Inc. Common Stock | B | C | B | $15.88 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Viatris is a globally diversified pharmaceutical company formed in November 2020 through the merger of Pfizer's Upjohn division and Mylan, establishing itself as one of the world's largest generic drug manufacturers serving over 165 countries. The company generates approximately 60% of revenues from established pharmaceutical products including Lipitor, Norvasc, Lyrica, and Viagra, while the remaining 40% comes from generic drugs and biosimilars. Viatris operates across over 10 therapeutic areas, with strategic focus on dermatology, ophthalmology, and gastroenterology for future growth.